Takip et
Teodora Djikic
Teodora Djikic
Faculty of Pharmacy, University of Belgrade
pharmacy.bg.ac.rs üzerinde doğrulanmış e-posta adresine sahip
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs
Z Gagic, D Ruzic, N Djokovic, T Djikic, K Nikolic
Frontiers in chemistry 7, 873, 2020
902020
Drug design for CNS diseases: polypharmacological profiling of compounds using cheminformatic, 3D-QSAR and virtual screening methodologies
K Nikolic, L Mavridis, T Djikic, J Vucicevic, D Agbaba, K Yelekci, ...
Frontiers in neuroscience 10, 198455, 2016
822016
Synthesis and screening of human monoamine oxidase‐A inhibitor effect of new 2‐pyrazoline and hydrazone derivatives
B Evranos‐Aksöz, İ Baysal, S Yabanoğlu‐Çiftçi, T Djikic, K Yelekçi, ...
Archiv der Pharmazie 348 (10), 743-756, 2015
332015
Synthesis, molecular docking and anticancer activity of diflunisal derivatives as cyclooxygenase enzyme inhibitors
GP Coşkun, T Djikic, TB Hayal, N Türkel, K Yelekçi, F Şahin, ...
Molecules 23 (8), 1969, 2018
282018
Application of in vitro PAMPA technique and in silico computational methods for blood-brain barrier permeability prediction of novel CNS drug candidates
M Radan, T Djikic, D Obradovic, K Nikolic
European Journal of Pharmaceutical Sciences 168, 106056, 2022
262022
Bicyclic α-Iminophosphonates as High Affinity Imidazoline I2 Receptor Ligands for Alzheimer’s Disease
S Abás, S Rodriguez-Arevalo, A Bagan, C Grinan-Ferre, F Vasilopoulou, ...
Journal of medicinal chemistry 63 (7), 3610-3633, 2020
252020
Synthesis, anticancer activity, and molecular modeling of etodolac‐thioether derivatives as potent methionine aminopeptidase (type II) inhibitors
I Çoruh, Ö Çevik, K Yelekçi, T Djikic, ŞG Küçükgüzel
Archiv der Pharmazie 351 (3-4), 1700195, 2018
212018
Benzofuranyl-2-imidazoles as imidazoline I2 receptor ligands for Alzheimer's disease
S Rodriguez-Arevalo, A Bagan, C Grinan-Ferre, F Vasilopoulou, M Pallas, ...
European journal of medicinal chemistry 222, 113540, 2021
182021
In silico identification of novel 5-HT2A antagonists supported with ligand- and target-based drug design methodologies
M Radan, D Ruzic, M Antonijevic, T Djikic, K Nikolic
Journal of Biomolecular Structure and Dynamics 39 (5), 1819-1837, 2021
152021
Human dopamine transporter: the first implementation of a combined in silico/in vitro approach revealing the substrate and inhibitor specificities
T Djikic, Y Martí, F Spyrakis, T Lau, P Benedetti, G Davey, P Schloss, ...
Journal of Biomolecular Structure and Dynamics 37 (2), 291-306, 2019
122019
The evaluation of drug-plasma protein binding interaction on immobilized human serum albumin stationary phase, aided by different computational approaches
D Obradović, M Radan, T Đikić, MP Nikolić, S Oljačić, K Nikolić
Journal of Pharmaceutical and Biomedical Analysis 211, 114593, 2022
82022
An Integrative in silico Drug Repurposing Approach for Identification of Potential Inhibitors of SARS‐CoV‐2 Main Protease
N Djokovic, D Ruzic, T Djikic, S Cvijic, J Ignjatovic, S Ibric, K Baralic, ...
Molecular Informatics 40 (5), 2000187, 2021
82021
Synthesis, Molecular Modelling and antibacterial activity against Helicobacter pylori of novel diflunisal derivatives as urease enzyme inhibitors
GP Coşkun, T Djikic, S Kalaycı, K Yelekçi, F Şahin, ŞG Küçükgüzel
Letters in Drug Design & Discovery 16 (4), 392-400, 2019
72019
Drug design for CNS diseases: Polypharmacological profiling of compounds using cheminformatic, 3D-QSAR and virtual screening methodologies. Front. Neurosci. 2016; 10: 265
K Nikolic, L Mavridis, T Djikic, J Vucicevic, D Agbaba, K Yelekci, ...
5
Design and Discovery of Kinase Inhibitors Using Docking Studies
T Djikic, Z Gagic, K Nikolic
Molecular Docking for Computer-Aided Drug Design, 337-365, 2021
12021
Deciphering Imidazoline Off‐targets by Fishing in the Class A of GPCR field
T Djikic, J Vucicevic, J Laurila, M Radi, N Veljkovic, H Xhaard, K Nikolic
Molecular informatics 39 (7), 1900165, 2020
12020
3D-Quantitative Structure-Activity Relationship and design of novel Rho-associated protein kinases-1 (ROCK1) inhibitors
M Beljkaš, J Rebić, M Radan, T Đikić, S Oljačić, K Nikolić
2nd International Conference on Chemo and Bioinformatics, BOOK OF …, 2023
2023
Virtual Docking, design and in silico ADMET profiling of novel Rho-associated protein kinases-1 (ROCK1) inhibitors
M Beljkaš, J Rebić, M Radan, T Đikić, S Oljačić, K Nikolić
2nd International Conference on Chemo and Bioinformatics ICCBIKG 2023, BOOK …, 2023
2023
Polypharmacological strategy in rational drug design of new dual 5HT2A/D2-R antagonists as potentially effective therapeutics of complex neurological and mental disorders
K Nikolić, M Radan, T Đikić
8th and final ERNEST Meeting" GPCR structure and function: The present and …, 2023
2023
Discovery of new chemotypes of dual 5-HT2A/D2 receptor antagonists with a strategy of drug design methodologies
M Radan, T Djikic, K Nikolic
Future Medicinal Chemistry 14 (13), 963-989, 2022
2022
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20